MedPath

Fedratinib for the Treatment of Myelofibrosis: A Review of Clinical Trial and Real-World Data

This article reviews the efficacy and safety of fedratinib in treating myelofibrosis, based on clinical trial data and real-world evidence. It highlights the drug's impact on spleen volume response, symptom improvement, and adverse effects, including gastrointestinal issues and hematologic toxicities.

Clinical Trial Data

  • Phase I Trial (2011): Assessed fedratinib's safety, tolerability, and efficacy in patients with high- or intermediate-risk primary or post PV/ET MF. The maximum tolerated dose was 680 mg/day, with common adverse events including nausea, vomiting, diarrhea, anemia, and thrombocytopenia. Spleen volume response rates >35% (SVR35) were achieved by 39% of patients by week 24 and 47% at week 48.
  • Phase II Study: Randomized 31 patients to receive fedratinib at 300, 400, or 500 mg once daily. The 400 mg dose showed the best spleen response, with 60% of patients responding at week 24, and also achieved the best symptom response.
  • JAKARTA Study (Phase III): Involved 289 previously untreated patients with high-risk or intermediate-2 risk primary or post PV/ET MF. Patients were randomized to receive either 400 mg or 500 mg of fedratinib daily, or placebo. SVR35 was 36% for the 400 mg group and 40% for the 500 mg group at week 24, compared to 1% for placebo.
  • JAKARTA-2 Study: Evaluated fedratinib in patients previously treated with ruxolitinib who demonstrated intolerance or disease progression. A SVR35 of 55% was achieved in evaluable patients, with a TSS response of 26%.

Real-World Data

  • Mayo Clinic Experience: Reported on 28 MF patients relapsed or refractory to ruxolitinib. Spleen response was evaluated in 24 patients, with only three patients (13%) exhibiting a reduction in spleen size. Symptom improvement was more frequently reported.
  • Community Oncology Practices Study: Included 150 patients previously treated with ruxolitinib. The mean spleen length decreased significantly from 16.0 cm at initiation to 7.2 cm at 6 months. Complete resolution of palpable spleen occurred in 21% of patients.
  • Retrospective US Cohort Study: Described outcomes of 150 MF patients receiving fedratinib, pacritinib, or other therapies after ruxolitinib. The fedratinib arm showed a median overall survival (OS) of 27.1 months, with 96.6% of patients alive at 6 months post-index.
  • Flatiron Health National Database Study: Compared survival in patients receiving fedratinib versus non-fedratinib therapy post-ruxolitinib. Median OS was not reached in the fedratinib group and was 17 months in the non-fedratinib group.

Conclusion

Fedratinib has shown efficacy in reducing spleen size and improving symptoms in patients with myelofibrosis, both in clinical trials and real-world settings. However, its benefits may be more pronounced in providing symptomatic relief rather than significant spleen size reduction. Adverse effects, particularly gastrointestinal and hematologic toxicities, are common but manageable.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Momelotinib and Pacritinib Show Promise in Alleviating Anemia and Transfusion Needs in Myelofibrosis

A real-world study indicates that momelotinib and pacritinib show favorable effects on anemia and reduce transfusion requirements in myelofibrosis patients.
Momelotinib treatment led to a statistically significant increase in hemoglobin levels after three months, along with a reduction in red blood cell units needed per month.

Navtemadlin Shows Promise in JAK Inhibitor-Refractory Myelofibrosis

Navtemadlin demonstrated a statistically significant spleen volume reduction in myelofibrosis patients who had relapsed or were refractory to JAK inhibitors.
The BOREAS trial showed navtemadlin nearly tripled spleen volume reductions and doubled symptom score improvements compared to best available therapy.

Flonoltinib and Selinexor Combinations Show Promise in Myelofibrosis Treatment

Flonoltinib demonstrated significant spleen and symptom response in myelofibrosis patients, suggesting it may be a new treatment option.
A phase 2 trial showed selinexor combined with ruxolitinib led to spleen length reduction and symptom alleviation in myelofibrosis patients previously treated with ruxolitinib.

Pelabresib Plus Ruxolitinib Shows Significant Benefit in Myelofibrosis Patients

Pelabresib combined with ruxolitinib significantly reduced splenomegaly in JAK inhibitor-naïve myelofibrosis patients, with 65.9% achieving a ≥35% spleen volume reduction at 24 weeks.
The combination therapy also demonstrated improvements in total symptom score, with a mean absolute change of -15.99 compared to -14.05 in the placebo arm.

Fedratinib Demonstrates Efficacy in Ruxolitinib-Refractory Myelofibrosis: FREEDOM2 Trial

Fedratinib shows significant spleen volume reduction (SVR) in myelofibrosis patients who have relapsed, are refractory, or are intolerant to ruxolitinib, according to the FREEDOM2 trial.
The FREEDOM2 trial demonstrated a 36% SVR with fedratinib compared to 6% with best available therapy (BAT) in ruxolitinib-refractory or intolerant patients.

Low-Dose Decitabine Shows Promise in Myelofibrosis Treatment

A phase II trial of low-dose subcutaneous decitabine demonstrated a 33% overall response rate in myelofibrosis (MF) patients, primarily improving cytopenias.
The treatment showed a median response duration of 7 months and a favorable safety profile with manageable non-hematologic toxicities.

Real-World Use of Fedratinib for Myelofibrosis Following Ruxolitinib Failure

A study on the real-world application of fedratinib for myelofibrosis patients after ruxolitinib failure shows significant spleen size reduction and symptom improvement.

Real-World Outcomes with Fedratinib in Myelofibrosis Patients Post-Ruxolitinib Discontinuation

A study comparing the baseline characteristics and survival outcomes of myelofibrosis patients receiving Fedratinib versus those not receiving Fedratinib after discontinuing Ruxolitinib in routine US clinical practice shows a trend towards increased overall survival with Fedratinib, though not statistically significant.

Fedratinib: A Comprehensive Review of Pharmacology, Efficacy, and Safety in Myelofibrosis Treatment

Fedratinib is an effective treatment for myelofibrosis (MF), improving splenomegaly and symptom burden in both JAK-inhibitor-naïve and ruxolitinib-pretreated patients.
The drug's mechanism involves selective JAK2 inhibition and off-target effects on FLT3 and BRD4, potentially offering benefits beyond JAK2 inhibition alone.

Ruxolitinib Demonstrates Sustained Efficacy in Myelofibrosis Treatment

Ruxolitinib, a JAK1/JAK2 inhibitor, has shown significant and durable improvements in splenomegaly and disease-related symptoms in patients with myelofibrosis (MF).
Long-term follow-up data confirms ruxolitinib's benefits across various patient subgroups, regardless of age, MF type, risk category, or JAK2 V617F mutation status.

Reference News

[1]
Fedratinib for the treatment of myelofibrosis: a critical appraisal of clinical trial and “real-world” data
nature.com · Jan 14, 2025

Fedratinib trials show efficacy in reducing spleen size and symptoms in myelofibrosis patients, with common adverse effe...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy